Submission of the manuscript is online via e-mail or

Tel: +7 903 250 5288

Editorial Correspondence e-mail

Publishing, Subscriptions, Sales and Advertising, Correspondence e-mail

Tel: +7 917 561 9505

SCImago Journal & Country Rank

    1. Volgograd State Medical University (Volgograd, Russian Federation)

    Keywords:non-alcoholic fatty liver disease,chronic heart failure,carbohydrate and fat metabolism,fatty liver index (FLI-index) index of fibrosis (NFS-index),ultrasonographic class of liver damage

    Abstract:The aim of the study was to determine the relationship between the presence of disorders of carbohydrate and lipid metabolism with the structural changes of the liver in patients with ischemic chronic heart failure and non-alcoholic fatty liver disease. Materials and methods. The study included 120 patients aged 45 to 65 years old with I-III functional class chronic heart failure, myocardial infarction from 6 to 12 months. All patients had symptoms of metabolic syndrome and diabetes mellitus type 2. Patients analyzed anthropometric data, blood pressure measurement, evaluation of the content of visceral fat, level of liver markers damage, carbohydrate and lipid metabolism by conventional laboratory techniques; HOMA insulin resistance index was calculated by Mattews D. and metabolic index by Roitberg G. E.; perform calculations steatosis index (FLI) and liver fibrosis (NFS), liver ultrasonography. Results: In patients with chronic heart failure and non-alcoholic fatty liver disease FLI - index and NFS - index significantly correlated with higher levels of LDL cholesterol and triglyceride levels, decrease of HDL cholesterol and high metabolic index. Increasing FLI-index significantly correlated with the percentage of visceral fat. The level of glycated hemoglobin was significantly higher in the group with initial ultrasonographic evidence of NAFLD. FLI - index significantly correlated with level of GGT, whereas the NFS - index correlated with level of alkaline phosphatase in the group IB - IC ultrasonic classes of hepatic steatosis. Conclusion: we have identified a relationship between disorders of carbohydrate and lipid metabolism with the structural changes of the liver in patients with ishemic chronic heart failure and non-alcoholic fatty liver disease.

      1. EASL-EASD-EASO Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease. Diabetologia, 2016, vol. 59, pp. 1121-1140.
      2. Драпкина О. М., Ивашкин В. Т. Эпидемиологические особенности неалкогольной жировой болезни печени в России (результаты открытого многоцентрового проспективного исследования наблюдения DIREGL 01903). Рос журн гастроэнтерол гепатол колопроктол., 2014, Т. 24, № 4, С. 32-38.
      3. Nonalcoholic fatty liver disease: A precursor of the metabolic syndrome. DigestiveandLiverDisease, 2015, vol. 47, pp. 181-190.
      4. Kanwar P., Nelson J. E., Yates K., et al. Association between metabolic syndrome and liver histology among NAFLD patients without diabetes. BMJ Open Gastro, 2016, vol. 3, pp. 1-9.
      5. Yang, K. C. et al. Association of Non-alcoholic Fatty Liver Disease with Metabolic Syndrome Independently of Central Obesity and Insulin Resistance. Sci. Rep., 2016, vol. 6, 27034; doi: 10.1038/srep27034 (2016).
      6. Friis-Liby I., Aldenborg F., Jerlstad P., et al. High prevalence of metabolic complications in patients with non-alcoholic fatty liver disease. Scand. J. Gastroenterol., 2004, vol. 39, pp. 864-869.
      7. Bellentani S., Bedogni G., Tiribelli C. Liver and heart: A new link? - ALT Predicts Heart Disease. Journal of Hepatology, 2008, vol. 49, pp. 300-302.
      8. Туркина С. В., Косивцова М. А., Шилина Н. Н., Стаценко М. Е. Функциональное состояние печени при нарушении микроциркуляции у больных хронической сердечной недостаточностью и сахарным диабетом 2 типа. Материалы Межрегиональной научно-образовательной конференции кардиологов и терапевтов. Специальный выпуск журнала Кардиоваскулярная терапия и профилактика, 2015, - С. 120-121.
      9. Yılmaz E. The diagnostic role of ultrasonograhyy in liver streatosis. The Turkish Journal of Gastroenterology, 1999, vol. 2, pp. 96-100.
      10. Рекомендации экспертов Всероссийского научного общества кардиологов по диагностике и лечению метаболического синдрома. Второй пересмотр. Практическая медицина, 2010, № 5 (44), с. 81-101.
      11. Ройтберг Г. Е., Дорош Ж. В., Шархун О. О. и др. Возможности применения нового метаболического индекса при оценке инсулинорезистентности в клинической практике. Рациональная фармакотерапия в кардиологии,2014, № 10 (3), с. 264-274.
      12. Bedogni G. et al. The Fatty Liver Index: a simple and accurate predictor of hepatic steatosis in the general population. BMC Gastroenterology, 2006, vol. 6, pp. 33-38.
      13. Angulo P. The NAFLD Fibrosis Score: A Noninvasive System ThatIdentifies Liver Fibrosis in Patients with NAFLD. HEPATOLOGY, 2007, vol. 45, № 4, - pp.846-854.
      14. Ekstedt M., Franzen L. E., Mathiesen U. L. et al. Survival and causes of death in patients with elevated liver enzymes associated with non-alcoholic fatty liver disease. J. Hepatol., 2006, vol. 44 (Suppl. 2), pp.40-41.
      15. Adams L. A., Talwalkar J. A. Diagnostic evaluation of nonalcoholic fatty liver disease. J. Clin. Gastroenterol., 2006, vol. 40 (3 Suppl. 1)., pp. 34-38.
      16. Day C. P. James O. F. Steatohepatitis: a tale of two ‘hits’? Gastroenterology, 1998, vol. 114, № 4, pp. 842-845.
      17. Yamaguchi K., Yang L., McCall S. et al. Inhibiting triglyceride synthesis improves hepatic steatosis but exacerbates liver damage and fibrosis in obese mice with non-alcoholic steatohepatitis. Hepatology, 2007, vol. 45, pp. 1366-1374.
      18. Kantartzis K., Peter A., Machicao F. et al. Dissociation between fatty liver and insulin resistance in humans carrying a variant of the patatin-like phospho- lipase 3 gene. Diabetes, 2009, vol. 58, pp. 2616-2623.
      19. Shen J., Wong G. L., Chan H. L. et al. PNPLA3 gene polymorphism accounts for fatty liver in community subjects without metabolic syndrome. Alimentary Pharmacology and Therapeutics, 2014, vol. 39, pp. 532-539.
      20. Ruttmann E., Brant L. J., Concin H. et al. Glutamyltransferase as a Risk Factor for Cardiovascular Disease Mortality. Circulation, 2005, vol.112, pp. 2130-2137.
      21. Dhingra R., Gona P., Wang T. J. et al. Serum g-GlutamylTransferase and Risk of Heart Failure in the Community. ArteriosclerThrombVascBiol., 2010, vol. 30, pp. 1855-1860.
      22. Wannamethee S. G., Whincup P. H., Shaper A. G., Lennon L. Naveed Sattarγ-Glutamyltransferase, Hepatic Enzymes, and Risk of Incident Heart Failure in Older Men. ArteriosclerThrombVasc Biol., 2012, vol. 32, pp. 830-835.
      23. Kozakova M., Palombo C., Eng M. P. et al. Fatty liver index, gamma-glutamyltransferase, and early carotid plaques. Hepatology, 2012, vol. 55(5), pp. 1406-1415.
      24. Atar A. I., Yilmaz O. C., Akin K. et al. Association between gamma-glutamyltransferase and coronary artery calcification. Int J Cardiol, 2013, vol. 167, pp. 1264-1267.
      25. Звенигородская Л. А., Хомерики С. Г., Егорова Е. Г. Морфологические изменения печени при инсулинорезистентности. Русский медицинский журнал, 2008, Том 16, № 4, С. 161-165.
      26. Ballestri S., Lonardo A., Romagnoli D. et al. Ultrasonographic fatty liver indicator, a novel score which rules out NASH and is correlated with metabolic parameters in NAFLD. Liver International, 2012, vol. 32, pp. 1242-1252.

    Full text is published :
    Read & Download full text

    1. Federal State Budget Educational Institution of Higher Education «Stavropol State Medical University» Health Ministry of Russian Federation (Stavropol, Russian Federation)

    Keywords:nonalcoholic fatty liver disease,nonalcoholic steatohepatitis,liver fibrosis,adhesion molecules,immunoglobulins superfamily

    Abstract:Aim of the work was to study relationship of molecules of immunoglobulins superfamily with histological variants of nonalcoholic fatty liver disease. Material and methods. Blood levels of parameters of immunoglobulins superfamily (ICAM-1, VCAM-1, PECAM-1) were studied in 40 patients (23 men, 17 women) with histologically proven nonalcoholic fatty liver disease in relationship with morphological changes in liver. Severe liver steatosis was revealed in 47.5 % of patients, nonalcoholic steatohepatitis was observed in 57.5 % of cases, moderate and severe liver fibrosis was present in 70 % of patients. The control group included 60 healthy volunteers. Results. The blood concentration of all adhesion molecules was increased in nonalcoholic fatty liver disease. The levels of ICAM-1 and VCAM-1 in blood increased and levels of PECAM-1 decreased with intensifying of fatty liver infiltration, reaching extreme values in cases of severe steatosis. Positive correlation between ICAM-1 and degree of steatosis was determined. In patients with parameters of nonalcoholic steatohepatitis score (NAS-II) of 5 and more points levels of ICAM-1 and VCAM-1 in blood were higher, than in group of patients with the minimal values of scale. Positive correlation of ICAM-1 and VCAM-1 with values of nonalcoholic steatohepatitis score was detected. Levels of ICAM-1, VCAM-1 and PECAM-1 in blood increased with intensifying of hepatic fibrotic changes and were maximal in severe fibrosis. Positive correlation of ICAM-1, VCAM-1 and PECAM-1 with fibrosis score was registered. Conclusion. Definition of adhesion molecules profile in nonalcoholic fatty liver disease allows to ascertain expressiveness of morphological changes and to stratify patients on groups with various morphological activity and liver fibrosis.

      1. Du J., Ma Y. Y., Yu C. H., Li Y. M. Effects of pentoxifylline on nonalcoholic fatty liver disease: a meta-analysis // World. J. Gastroenterol. - 2014. - Vol. 20, № 2. - P. 569-577.
      2. Younossi Z. M., Koenig A. B., Abdelatif D. et al. Global epidemiology of nonalcoholic fatty liver disease - Meta-analytic assessment of prevalence, incidence, and outcomes // Hepatology. - 2016. - Vol. 64, № 1. - P. 73-84.
      3. Promrat K., Kleiner D. E., Niemeier H. M. et al. Randomized controlled trial testing the effects of weight loss on nonalcoholic steatohepatitis // Hepatology. - 2010. - Vol. 51. - P. 121-129.
      4. Гилязова Г. И., Мухорамова И. С., Руденко Ю. А., Корой П. В. Роль молекул адгезии в иммунном ответе // Вестник молодого ученого. - 2012. - № 2. - С. 21-27.
      5. Sookoian S., Castaño G. O., Burgueño A. L. et al. Circulating levels and hepatic expression of molecular mediators of atherosclerosis in nonalcoholic fatty liver disease // Atherosclerosis. - 2010. - Vol. 209, № 2. - P. 585-591.
      6. Thakur M. L., Sharma S., Kumar A. et al. Nonalcoholic fatty liver disease is associated with subclinical atherosclerosis independent of obesity and metabolic syndrome in Asian Indians // Atherosclerosis. - 2012. - Vol. 223, № 2. - P. 507-511.
      7. VanSaun M. N., Mendonsa A. M., Gorden D. L. Hepatocellular proliferation correlates with inflammatory cell and cytokine changes in a murine model of nonalchoholic fatty liver disease // PLoS ONE. - 2013. - Vol. 8, № 9. - Р. e73054.
      8. Mosa T. E., Shehatta A. S., Khayyal A. A. et al. High serum levels of endothelial adhesion molecules E-selectin, ICAM-1 and VCAM in fatty liver patients // Asian. J. Biochem. - 2011. - Vol. 6. - P. 160-170.
      9. Söderberg C., Marmur J., Eckes K. et al. Microvesicular fat, intercellular adhesion molecule-1 and regulatory T-lymphocytes are of importance for the inflammatory process in livers with non-alcoholic steatohepatitis // APMIS. - 2011. - Vol. 119, № 7. - P. 412-420.
      10. Weghuber D., Roden M., Franz C. et al. Vascular function in obese children with non-alcoholic fatty liver disease // Int. J. Pediatr. Obes. - 2011. - Vol. 6, № 2. - P. 120-127.
      11. Borghi-Scoazec G., Collardeau-Frachon S., Dumortier J., Scoazec J.-Y. Perisinusoidal fibrosis is associated with changes in sinusoidal endothelial cell (SEC) phenotype suggestive of a transdifferentiation process // J. Hepatol. - 2010. - Vol. 52, Suppl. 1. - S. 356.
      12. Lv P., Luo H. S., Zhou X. P. et al. Reversal effect of thalidomide on established hepatic cirrhosis in rats via inhibition of nuclear factor-kappaB/inhibitor of nuclear factor-kappaB pathway // Arch. Med. Res. - 2007. - Vol. 38, № 1. - P. 15-27.
      13. Корой П. В., Ягода А. В., Гилязова Г. И., Мухорамова И. С. Медиаторы межклеточных взаимодействий и гистологические проявления хронической вирусной патологии печени // Росс. журн. гастроэнтерол., гепатол., колопроктол. - 2014. - № 5. - С. 22-28.
      14. Корой П. В., Мухорамова И. С., Ягода А. В. Молекулы адгезии и гистологическая картина при хронических вирусных заболеваниях печени // Мед. вестник Северного Кавказа. - 2012. - № 2. - С. 48-51.
      15. Anderson N., Borlak J. Molecular mechanisms and therapeutic targets in steatosis and steatohepatitis // Pharmacol. Rev. - 2008. - Vol. 60, № 3. - P. 311-357.
      16. Thabut D., Tazi K. A., Bonnefont-Rousselot D. et al. High-density lipoprotein administration attenuates liver proinflammatory response, restores liver endothelial nitric oxide synthase activity, and lowers portal pressure in cirrhotic rats // Hepatology. - 2007. - Vol. 46. - P. 1893-1906.
      17. Musso G., Gambino R., De Michieli F. et al. Adiponectin gene polymorphisms modulate acute adiponectin response to dietary fat: Possible pathogenetic role in NASH // Hepatology. - 2008. - Vol. 47. - P. 1167-1177.
      18. Kawasuji A., Hasegawa M., Horikawa M. et al. L-selectin and intercellular adhesion molecule-1 regulate the development of Concanavalin A-induced liver injury // J. Leukoc. Biol. - 2006. - Vol. 79, № 4. - P. 696-705.
      19. Nagarajan P., Kumar M. J. M., Venkatesan R. et al. Genetically modified mouse models for the study of nonalcoholic fatty liver disease // World. J. Gastroenterol. - 2012. - Vol. 18, № 11. - P. 1141-1153.
      20. Goel R., Boylan B., Gruman L. et al. The proinflammatory phenotype of PECAM-1-deficient mice results in atherogenic diet-induced steatohepatitis // Am. J. Physiol. Gastrointest. Liver. Physiol. - 2007. - Vol. 293. - P. G1205-1214.
      21. Vernon G., Baranova A., Younossi Z. M. Systematic review: the epidemiology and natural history of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis in adults // Aliment. Pharmacol. Ther. - 2011. - Vol. 34. - P. 274-285.
      22. Kukla M., Zwirska-Korczala K., Gabriel A. et al. Soluble platelet-endothelial cell adhesion molecule-1 and soluble vascular cell adhesion molecule-1: role in pathogenesis and diagnosis of chronic hepatitis C and association with response to antiviral therapy // Therap. Adv. Gastroenterol. - 2009. - Vol. 2, № 2. - P. 79-90.
      23. Ip E., Farrell G., Hall P. et al. Administration of the potent PPARalpha agonist, Wy-14,643, reverses nutritional fibrosis and steatohepatitis in mice // Hepatology. - 2004. - Vol. 39, № 5. - P. 1286-1296.
      24. Thakur V., Pritchard M. T., McMullen M. R., Nagy L. E. Adiponectin normalizes LPS-stimulated TNF-alpha production by rat Kupffer cells after chronic ethanol feeding // Am. J. Physiol. Gastrointest. Liver. Physiol. - 2006. - Vol. 290, № 5. - Р. G998-1007.
      25. Tomizawa A., Hattori Y., Kasai K., Nakano Y. Adiponectin induces NFkappaB activation that leads to suppression of cytokine-induced NF-kappaB activation in vascular endothelial cells: globular adiponectin vs. high molecular weight adiponectin // Diab. Vasc. Dis. Res. - 2008. - Vol. 5. - P. 123-127.
      26. Гейвандова Н. И., Ягода А. В., Фалеева О. В., Корой П. В. Гормоны жировой ткани и гистологическая картина печени при хроническом гепатите С // Клин. перспективы гастроэнтерол., гепатол. - 2012. - № 4. - С. 17-22.
      27. Ягода А. В., Корой П. В. Функциональная активность тромбоцитов и печеночный фиброз при хронической вирусной патологии печени. Возможности неинвазивной диагностики // Экспер. клин. гастроэнтерол. - 2006. - № 5. - С. 73-76.

    Full text is published :
    Read & Download full text

    1. I. M. Sechenov First Moscow State Medical University (Moscow, Russian Federation)
    2. Federal Research and Clinical Centre of Physical-Chemical Medicine (Moscow, Russian Federation)

    Keywords:chronic hepatitis C,cepeginterferon alpha 2b,simeprevir,liver elastometry,recombinant HCV RF1 2k / 1b

    Abstract:The features of the application of pegylated interferon - Сepeginterferon alfa2b (cepeg-IFN) on the results of treatment of 20 patients with chronic hepatitis C in outpatient practice. The analysis of the clinical, biochemical, virological data and transient liver elastometry on the background of antiviral therapy with cepeg-IFN. Based on these data is justified is not the worst in comparison with foreign analogues the efficacy and safety of the original domestic product for the treatment of patients with chronic hepatitis C, not previously treated with antiviral therapy, without a high degree of fibrosis or cirrhosis. Demonstrated clinical example of treatment failure associated with infection with a recombinant virus 2k1b and proposes an approach to the diagnosis of this variant infection

      1. EASL Recommendations on Treatment of Hepatitis C 2015. J. Hepatol. 2015;63(1):199-236.
      2. EASL Recommendations on Treatment of Hepatitis C 2016. J Hepatol (2016), Ссылка активна 05.01.2017. Доступно по: jhep.2016.09.001
      3. Lavanchy D. The global burdgen of hepatitis C. Liver Int 2009; 29 (Suppl 1):74-81.
      4. Sheppard C. W., Finelli L., Alter M. J. Global epidemiology of hepatitis C virus infection. Lancet Infect. Dis 2005; 5:558-67
      5. Федеральная служба по надзору в сфере защиты прав потребителей и благополучия человека. Инфекционная заболеваемость в Российской Федерации за январь - декабрь 2015года (по данным формы № 1 «Сведения об инфекционных и паразитарных заболеваниях»). Ссылка активна на 05.09.2016. Доступно по: ELEMENT_ID=5525
      6. Ghany M. G., Nelson D. R., Strader D. B., Thomas D. L., Seeff L. B. An update on treatment of genotype 1 chronic hepatitis C virus infection: 2011 practice guideline by the American Association for the Study of Liver Diseases. Hepatol 54:1433-44
      7. Sarrazin C., Christophe Hezode Ch., Zeuzem S., JeanMichel Pawlotsky J. M. Antiviral strategies in hepatitis C virus infection. Hepatol 2012; 88-100.
      8. Ющук Н. Д., Знойко О. О., Дудина К. Р. и соавт. Социально-экономическое бремя гепатита С: методология оценки и трудности расчета в Российской Федерации. Ссылка активна на 05.09.16. Доступно по:
      9. Маевская М. В., Знойко О. О., Климова Е. А. Лечение больных хроническим гепатитом С препаратом цепэгинтерферон альфа-2b в сочетании с рибавирином (Итоговые результаты рандомизированного сравнительного клинического исследования). РЖГГК. 2014;2(24):53-64.
      10. Kalinina O., Norder H., Mukomolov S., Magnius L. O. A natural intergenotypic recombinant of hepatitis C virus identified in St. Petersburg // J Virol. 2002 Apr; 76 (8): 4034-4043. DOI: 10.1128/jvi.76.8.4034-4043.2002.
      11. Шахгильдян И. В., Михайлов М. И., Онищенко Г. Г. Характеристика отдельных групп высокого риска заражения вирусами гепатитов В, С и D. Дальневосточный журнал инфекционных болезней. 2004; 5: 3-112.
      12. Hedskog C, Doehle B, Chodavarapu K, Gontcharova V, Crespo Garcia J, De Knegt R, et al. Characterization of hepatitis C virus inter-genotypic recombinant strains and associated virologic response to sofosbuvir/ribavirin. Hepatology. 2014 Aug 7

    Full text is published :
    Read & Download full text

    1. North-Western State Medical University of Mechnikov (St. Petersburg, Russian Federation)

    Keywords:chronic hepatitis,regenerative therapy,lipid metabolism,non-alcoholic fatty liver disease

    Abstract:Chronic hepatitis is a common socially significant pathology in the world. One of the manifestations of chronic hepatitis B is a violation of lipid metabolism, affecting the course and progression of the underlying disease. Despite holding a large number of studies on the correction of lipid status in patients with chronic hepatitis, treatment of lipid disorders problem remains urgent. In this regard, the aim of our study was to evaluate the effect of combination therapy with the mononuclear fraction of blood compared with standard therapy on the dynamics of lipid metabolism in patients with chronic hepatitis.

      1. Аутоиммунные заболевания печени: клиника, диагностика, лечение / Е. В. Голованова и др. // Экспериментальная и клиническая гастроэнтерология- 2015. - Вып.119, № 7. - С. 97-107
      2. Неалкогольная жировая болезнь печени: клиника, диагностика, лечение / Л. Б. Лазебник и др. // Экспериментальная и клиническая гастроэнтерология- 2015. - Вып.119, № 7. - С. 85-96
      3. Неалкогольный стеатогепатит и билиарный сладж у лиц с метаболическим синдромом / В. Г. Радченко и др. // Терапевтический архив- 2016. - № 9. С. 78-83
      4. Приходько Е. М., Селиверстов П. В., Радченко В. Г. Возможности регенеративной терапии в лечении больных хроническим гепатитом // Гастроэнтерология Санкт-Петербурга- 2016. - № 1-2. М.27
      5. Пути верификации неалкогольной жировой болезни печени / П. В. Селиверстов и др. // Врач- 2015. - № 10. С. 53-55
      6. Хронические заболевания печени в практике врача терапевта / Д. Б. Цурцумия и др. // Ремедиум Приволжье-2016. - № 9. С. 22-23
      7. Grisham J. W. A mophologic study of deoxyribonucleic acid synthesis and cell proliferation in regenerating liver; autoradiography with thymidine-H3 / J. W. Grisham // Cancer Res. - 1962. - V. 22. - P. 842-849.
      8. Growth factors increase retroviral transduction but decrease clonogenic potential of umbilical cord blood CD 34+ cells / Corrias M. V. et al. // Haematologica. - 1998. - V. 83. - P. 580-6.
      9. Hepatic stem cells: inside and outside the liver? / Alison M. R. et al. // Cell Prolif. - 2004 - Vol.37. -P.1-21
      10. High-efficiency gene transfer into ex vivo expanded human hematopoietic progenitor and precursor cells by adenovirus vectors / Frey B. M. et al. // Blood. - 1998.-V. 91.-P. 2781-92.
      11. Hepatocytes derived from bone marrow stem cells demonstrated polyploidization / Forbes S. J. et al. // J. Hepatology. - 2001. - Vol. 34. (Suppl. 1). - P. 20-21.
      12. Heterogeneity among human bone marrow-derived mesenchymal stem cells and neural progenitor cells / Vogel W. et al. // Haematologica. - 2003. - V. 88. - P. 121.
      13. Higgins GM. Experimental pathology of the liver: I. Restoration of the liver of the white rat following partial surgical removal / GM Higgins, RM Anderson // Arch Pathol. - 1931. - V. 12. - P. 186-202.
      14. Hawley T. S. Methods in Molecular Biology: Flow Cytometry Protocols, 2nd ed. / Hawley T. S., Hawley R. G., Totowa, N.J. - Humana Press Inc., 2004. - P. 434.
      15. The role of the telomere test in predicting the efficacy of therapy in patients of nonalcoholic fatty liver disease / Е. Prihodko at all. // Internationaler Kongress Fachmesse «Euromedica Hannover 2015». Р. 67.

    Full text is published :
    Read & Download full text

    1. Astrakhan State Medical University (Astrakhan, Russian Federation)

    Keywords:chronic hepatitis,liver cirrhosis,tumor necrosis factor,soluble receptors of tumor necrosis factor II type

    Abstract:The Aim was to investigate of clinical and diagnostic value of change of concentration of tumor necrosis factor (TNF) and also soluble receptors II type of tumor necrosis factor (sTNF-RII) in chronic hepatitis (CH) and liver cirrhosis (LC). Material and methods. 65 CH and 64 LC patients and 25 healthy volunteers were included in the investigation. TNF and sTNF-RII concentrations were assessed by the ELISA method. Results. The average TNF level in CH and LC was authentically (p<0,05) increased in comparison with the donors (84.12±10.92 IU/ml and 138.14±19.98 IU/ml cons 23.54±6.02 IU/ml). The sTNF-RII concentration in CH and LC was significantly (p<0,05) increased in comparison with the norm (in CH 7.33±0.32 IU/ml, in LC 13.15±2.19 IU/ml and in control 3.54±0.39 IU/ml). The TNF and sTNF-RII levels were significantly (p<0,05) increased in viral CH and LC in comparison with the alcoholic etiology and norm. The TNF and sTNF-RII increasing associated with the activity of inflammation and severity of LC class on the Child-Pugh score.

      1. Козлова И. В., Пахомова А. Л. Практическая гастроэнтерология: руководство для врачей в 2 ч. - М.: Дрофа, 2010, 495 с.
      2. Комаров Ф. И., Осадчук М. А., Осадчук A. M. Практическая гастроэнтерология. - M.: МИА, 2010, 480с.
      3. Стрижаков А. Н., Герадзе В. Н. Современное состояние проблемы цирроза печени. Российский журнал гастроэнтерологии, гепатологии и колопроктологии, 2009, Т. 19, № 1, С. 87-88
      4. Bell B. P., Manos M. M., Zaman A. et al. The epidemiology of newly diagnosed chronic liver disease in gastroenterology practices in the United States: results from population-based surveillance. Am. J. Gastroenterol., 2008, V. 103, P. 2727-2736.
      5. Ивашкин В. Т., Шульпекова О. Ю., Лукина Е. А. Классические провоспалительные цитокины и их биологические эффекты при заболеваниях печени. Молекулярная медицина, 2003, № 3, С. 34-43.
      6. Кетлинский С. А., Симбирцев А. С. Цитокины /СПб: Фолиант,2008.-552с.
      7. Albillos A, Lario M, Alvarez-Mon M. Cirrhosis-associated immune dysfunction: distinctive features and clinical relevance. J. Hepatol., 2014, 61(6), Р. 1385-96.
      8. Tilg H., Kaser A., Mosher A. R. How to modulate inflammatory cytokines in liver diseases. Liver Int., 2006, № 9, P. 1029-39.
      9. Ягода А. В., Гейвандова Н. И., Хубиев Ш. М., Цупрунова Д. С. Фактор некроза опухоли при хронических вирусных гепатитах: патогенетическая роль, пути фармакологической коррекции. Иммунология, 2000, № 2, С. 36-38.
      10. Астахин А. В., Левитан Б. Н., Афанасьев С. С. и соавт. Уровень фактора некроза опухоли-а и интерлейкина-4 в сыворотке крови больных хроническим гепатитом // Журнал микробиологии, эпидемиологии, иммунобиологии, 2004, № 2, С. 46-50
      11. Булатова И.А, Третьякова Ю. И., Щёкотова А. П. и соавт. Влияние фактора некроза опухоли альфа и полиморфизма его гена (RS 1800629) на тяжесть и прогрессирование хронического гепатита и язвенного колита.// Экспериментальная и клиническая гастроэнтерология, 2016, № 3 (127),С. 9-14
      12. Mourtzikou A., Alepaki M., Stamouli M. et al. Evaluation of serum levels of IL-6, TNF-α, IL-10, IL-2 and IL-4 in patients with chronic hepatitis. Inmunologia, 2014, V 33, № 2, С. 41-50.
      13. Diez-Ruiz A., Tilz G. P., Zangerle R. Soluble receptors for tumour necrosis factor in clinical laboratory diagnosis. Eur. J. Haematol., 1995, V 54, № 1, P. 8-14.
      14. Esteve E., Botas P., Delgado E. Soluble TNF-alpha receptor 2 produced by alternative splicing is paradoxically associated with markers of liver injury. Clin. Immunol., 2007, V 123, № 1, P. 89-94.
      15. Левитан Г. Б., Астахин А. В., Ларина Н. Н., Левитан Б. Н. Растворимые рецепторы фактора некроза опухолей типа II и этиология хронических гепатитов и циррозов печени. Астраханский медицинский журнал, 2010, Т. 5, № 3, С. 41-44.
      16. Shawky A. F., Nehal H. E., Nagwa A. M., Osama M. A. Diagnostic Value of Serum Level of Soluble Tumor Necrosis Factor Receptor IIα in Egyptian Patients With Chronic Hepatitis C Virus Infection and Hepatocellular Carcinoma. Hepat. Mon. 2014,14 (9): e19346.

    Full text is published :
    TUMOR NECROSIS FACTOR AND ITS SOLUBLE RECEPTORS II TYPE IN CHRONIC HEPATITIS AND LIVER CIRRHOSIS. Experimental and Clinical Gastroenterology Journal. 2017;138(02):62-66
    Read & Download full text

    1. I. M. Sechenov First Moscow State Medical University (Moscow, Russian Federation)

    Keywords:gastroesophageal reflux disease,non-erosive and erosive form,refractory form,nitric oxide synthase,endothelin-1,quality of life,the type of attitude to the disease

    Abstract:Revealed clinical and psycho-physical manifestations, especially the pathogenesis, endoscopic and morphological pattern of mucosal pathology Gastroesophageal Zone in elderly patients with erosive and non-erosive form of gastroesophageal reflux disease. A total of 226 patients studied nosology. Applied clinical, endoscopic, morphological, immunohistochemical methods. Increasing the number and functional activity of the stomach and esophagus APUD cell producing nitric oxide synthase and endothelin-1 in patients in comparison with comparison groups, suggests their main pathogenic factor of the disease. Cell hyperplasia cells secreting nitric oxide synthase and endothelin-1, more than twice, there is the formation of refractory form of the disease.

      1. Васcерман Л. И., Иовлев Б. В., Карлова Э. Б. и соавт. Психологическая диагностика отношения к болезни // пособие для врачей. - 2005. - 32с.
      2. Ивашкин В. Т. Гастроэзофагеальная рефлюксная болезнь. Рекомендации по диагностике и лечению / Трухманов А. С., Шептулин А. А., Баранская Е. К., Лапина Т. Л., Сторонова О. А., Кайбышева В. О./. - М., - 2013. - 20 с.
      3. Маев И. В., Самсонов А. А., Андреев Н. Г. Симптом изжоги: привычный дискомфорт или серьезная проблема?//Фарматека. -2011. -№ 10.
      4. Осадчук М. А., Осадчук А. М., Балашов Д. В. и соавт. Рефрактерная форма гастроэзофагеальной рефлюксной болезни: клинико-эндоскопические, функциональные и морфофункциональные критерии //Росс. журн. гастроэнтерол., гепатол., колопроктол. - 2011. - № 2. - С. 30-36.
      5. Furuta T, Shimatani T, Sugimoto M, Ishihara S, Fujiwara Y, Kusano M, Koike T, Hongo M, Chiba T, Kinoshita Y. Acid-Related Symptom Research Group. Investigation of pretreatment prediction of proton pump inhibitor (PPI)-resistant patients with gastroesophageal reflux disease and the dose escalation challenge of PPIs-TORNADO study: a multicenter prospective study by the Acid-Related Symptom Research Group in Japan. J Gastroenterol. 2011;14:1273-1283.
      6. Herregods T. V., Troelstra M., Weijenborg P. W., Bredenoord A. J., Smout A. J. Patients with refractory reflux symptoms often do not have GERD. Neurogastroenterol Motil. 2015 Jun 18. doi: 10.1111/nmo.12620.
      7. Sugimoto M, Uotani T, Ichikawa H, Andoh A, Furuta T. Gastroesophageal Reflux Disease in Time Covering Eradication for All Patients Infected with Helicobacter pylori in Japan. Digestion. 2016;93(1):24-31. doi: 10.1159/000441741.
      8. Takeshima F, Hashiguchi K, Onitsuka Y, Tanigawa K, Minami H, Matsushima K, Akazawa Y, Shiozawa K, Yamaguchi N, Taura N, Ohnita K, Ichikawa T, Isomoto H, Nakao K. Clinical Characteristics of Patients with Gastroesophageal Reflux Disease Refractory to Proton Pump Inhibitors and the Effects of Switching to 20 mg Esomeprazole on Reflux Symptoms and Quality of Life. Med Sci Monit. 2015 Dec 31;21:4111-21
      9. Ware J. E. The MOS 36-item short form health survey (SF-36): conceptual framework and item selection / J. E. Ware, C. D. Sherbourne // Medical Care. 1992. Vol. 30. P. 473-483.
      10. Yoshiyasu Kono, Ryuta Takenaka, Yoshiro Kawahara, Hiroyuki Okada, Keisuke Hori, Seiji Kawano, Yasushi Yamasaki, Koji Takemoto, Takayoshi Miyake, Shigeatsu Fujiki, and Kazuhide Yamamoto. Chromoendoscopy of gastric adenoma using an acetic acid indigocarmine mixture. World J Gastroenterol. May 7, 2014; 20(17): 5092-5097.

    Full text is published :
    Read & Download full text

    1. North-Western Medical University named after I. I. Mechnikov (St. Petersburg, Russian Federation)
    2. St.-Petersburg State Medical University named after I. P. Pavlov (St. Petersburg, Russian Federation)

    Keywords:lung cancer,chemotherapy,gastrointestinal complaints

    Abstract:Chemotherapy, used in patients with oncological diseases, leads to damage of a mucous membrane of gastrointestinal tract. 60 % of patients treated by chemotherapy have stools disorders. The article presents the data of the study of the severity of gastrointestinal complaints in patients with lung cancer, chemotherapy, the nature of the influence appointed in the schemes of the treatment of lung cancer anticancer drugs, shows the possibilities of correction of the revealed violations. Using of probiotics in these patients leads to decrease of gastrointestinal complains.

      1. Гржибовский А. М. Анализ количественных данных для двух независимых групп / А. М. Гржибовский // Экология человека. - 2008. - № 2. - С. 54-61.
      2. Ионова Т. И., Новик А. А. Исследование качества жизни у больных лимфомами // Вестн. Межнац. центра исследования КЖ. - 2006. - № 7-8. С. 121-137.
      3. Казюлин А. Н., Кучерявый Ю. А., Гайдамака Е. В. Факторы риска и частота токсического поражения желудочно-кишечного тракта при проведении противоопухолевой химиотерапии рака молочной железы // Газета «Новости медицины и фармации». - 2007. - № 226 - С. 15-17.
      4. Карпинская Н. П. Колонизационная резистентность слизистой оболочки полости рта у больных раком легкого в условиях противоопухолевой химиотерапии: Автореферат диссертации на соискание ученой степени к. м. н.: 14.00.16 / Карпинская Наталья Павлиновна. - Томск, 2006. - 18 с.
      5. Новик А. А., Ионова Т. И. Руководство по исследованию качества жизни в медицине. - СПб.: Издательский Дом «Нева»; М.: «ОЛМА-ПРЕСС Звездный мир», 2002.-320с., Новик А. А., Ионова Т. И., Кайнд П. Концепция исследования качества жизни в медицине. - СПб.: ЭЛБИ, 1999. - 140 с.
      6. Поддубная И. В., Орел Н. Ф., Смирнова Н. Б., Егоров Г. Н. Побочные реакции и осложнения противоопухолевой терапии и борьба с ними // Химиотерапия онкологических заболеваний. - М., 2000. - С. 336-359.
      7. Чиссов В. И., Старинский В. В., Петрова Г. В. Состояние онкологической помощи населению России в 2009 году. М.: ФГУ «МНИОИ им. П. А. Герцена Росмедтехнологий». - 2010. - 196 с.
      8. Cancer Statistics, 2009 / A. Jemal, R. Siegal, E. Ward, Y. Hao, J. Xu, M. Thun // CA Cancer J. clin. - 2009. - № 59. - P. 275-249. 111.
      9. Sánchez-Lara K, Ugalde-Morales E, Motola-Kuba D, Green D. Gastrointestinal symptoms and weight loss in cancer patients receiving chemotherapy. Br J Nutr. - 2012, Jun. 1 - Vol. 2. - P. 1-4. 165.
      10. van Vliet MJ, Tissing WJ, Dun CA, Meessen NE, Kamps WA, de Bont ES, Harmsen HJ. Chemotherapy treatment in pediatric patients with acute myeloid leukemia receiving antimicrobial prophylaxis leads to a relative increase of colonization with potentially pathogenic bacteria in the gut. Clin. Infect. Dis. - 2009. - Vol. 49(2) - P. 262-270. 179.
      11. World cancer report 2008 / Ed. by P. Boyle, B. Levin - WHO, Lyon, IARC: - 2008. - 511 p. 184.

    Full text is published :
    CORRECTION OF DIGESTIVE DISORDERS BY PROBIOTICS IN LUNG CANCER PATIENTS WITH CHEMOTHERAPY. Experimental and Clinical Gastroenterology Journal. 2017;138(02):71-76
    Read & Download full text

    1. Saratov State Medical University of V. I. Razumovsky (Saratov, Russian Federation)

    Keywords:Acute intestinal infections,the treatment of acute intestinal infections,succinate-containing drugs,Reamberinpharmacoeconomic efficiency

    Abstract:The aim of the research: the study of features of clinical course of acute intestinal infections (AII) on the background of coronary heart disease (CHD), diabetes (D), mental and behavioral disorders on the background of alcohol consumption (AC); development of pathogenetic therapy for these comorbid conditions by means of using succinate-containing drugs. Materials and Methods: 197 patients with AII (without associated diseases, and with CHD, D, AC) were examined in dynamics. The patients received conventional infusion therapy or 1,5 % solution of Reamberin at 10 mg per 1 kg of body weight. Pharmacoeconomic efficiency of using Reamberin was calculated. Results: Associated pathology determines more severe course of AII and possibility of complications, including decompensation of chronic disease. Introduction of Reamberin in the infusion therapy for patients with AII enabled proved decrease in the number of existing symptoms in all groups by the second day of treatment, as well as decrease in the persistence of the main symptoms of AII. The absence of cases of decompensation of chronic disease in patients receiving Reamberin was noted, in cases of their presence on the background of traditional therapy. Specific economy as a result of using Reamberin in the complex therapy of AII was 23383,5 rubles mainly due to the reduction of the duration of the disease and more rapid vocational rehabilitation. Conclusion: The presence of comorbid pathology affects the typical manifestations of AII, which requires optimization of therapy. The findings show the ability of Reamberin to influence the clinical course of AII, including in cases with associated diseases, by reducing the persistence of the main symptoms of the disease as well as the number of complications associated with decompensation of chronic conditions. High cost-effectiveness of using Reamberin in the treatment of AII, along with a proven positive clinical effect, is an important argument in favor of the widespread use of the succinate-containing drugs in clinical practice.

      1. Государственный доклад «О состоянии санитарно-эпидемиологического благополучия населения в Российской Федерации в 2015 году»
      2. State report “The state of sanitary and epidemiological welfare of the population in the Russian Federation in 2015”
      3. Здравоохранение в России. 2015: Стат.сб. Росстат. - М., 2015. - 174 с.
      4. Health care in Russia. 2015: Rosstat. - M., 2015. - 174 p.
      5. Тихонова Е. О., Ляпина Е. П., Перминова Т. А., Сатарова С. А. Особенности течения острых кишечных инфекций на фоне психических и поведенческих расстройств, вызванных употреблением алкоголя. Инфекционные болезни. Приложение 1: Материалы VIII Ежегодного Всероссийского Конгресса по инфекционным болезням (Москва, 28-30 марта 2016 г.), 2016, т. 14, с. 279.
      6. Tikhonovа E. O., Lyapina E. P., Perminovа T. A., Satarovа S. A. A course of acute intestinal infections in the background of mental and behavioral disorders caused by alcohol. Infectious diseases. Application 1: Materials of the VIII-th Annual All-Russian Congress on Infectious Diseases (Moscow, 28-30 March 2016), 2016, vol.14, p. 279.
      7. Реамберин: клинические и экспериментальные исследования / Реферативный сборник научных работ, процитированных в PubMed (база данных медицинских и биологических публикаций) в 2012 году / Под редакцией В. Г. Белова. - СПб., 2013. - 150 с. Reamberin: clinical and experimental studies / Abstract collections of scientific papers cited in PubMed (base of medical and biological publications data) 2012 / Edited by V. G. Belov. - SPb., 2013. - 150 p.
      8. Заплутанов В. А., Романцов М. Г., Тихонова Е. О. и соавт. Особенности течения острых кишечных инфекций с оценкой эффективности патогенетической терапии. Антибиотики и химиотерапия, 2012, т. 57, № 9-10, cc. 17-24.
      9. Zaplutanov V. A., Romantsov M. G., Tikhonova E. O. et al. A course of acute intestinal infections with the assessment of the effectiveness of pathogenetic therapy. Antibiotics and chemotherapy, 2012, vol.57, № 9-10, pp. 17-24.
      10. Шульдяков А. А., Блинникова Е. Н., Соболева Л. А., Савинова Г. А. Оптимизация метаболической терапии хронических вирусных гепатитов. Вестник Санкт-Петербургской государственной медицинской академии им. И. И. Мечникова, 2009, № 1, cc. 156-159.
      11. Shuldyakov A. A., Blinnikova E. N., Soboleva L. A., Savinova G. A. Optimization of the metabolic therapy of chronic viral hepatitis. Bulletin of St. Petersburg State Medical Academy of I. I. Mechnikov, 2009, № 1, pp.156-159.
      12. Зубарева С. В., Шульдяков А. А., Трубецков А. Д. и соавт. Метаболическая терапия при хроническом бруцеллезе как средство коррекции эндотоксикоза и функциональных нарушений миокарда. Вестник Санкт-Петербургской государственной медицинской академии им. И. И. Мечникова, 2008, № 3, cc. 93-95.
      13. Zubareva S. V., Shuldyakov A. A., Trubetskov A. D. et al. Metabolic therapy in chronic brucellosis as a means of correcting endotoxemia and myocardial function disorders. Bulletin of St. Petersburg State Medical Academy of I. I. Mechnikov, 2008, № 3, pp. 93-95.
      14. Маркевич П. С., Даниленко С. Ю., Янкин А. В. Роль препарата «Цитофлавин» в клинической практике. Бюллетень ВСНЦ СО РАМН, 2010, № 3 (73), cc. 109.
      15. Markevitch P. S., Danilenko S. Y., Yankin A. V. The role of the drug “Citoflavin” in clinical practice. Bulletin ESSC SB RAMS, 2010, № 3 (73), pp. 109.
      16. Markevitch P. S., Danilenko S. Y., Yankin A. V. The role of the drug “Citoflavin” in clinical practice. Bulletin ESSC SB RAMS, 2010, № 3 (73), pp. 109.
      19. 5236cbc
      20. Маржохова М. Ю. Уровень веществ низкой и средней молекулярной массы как показатель эндотоксикоза у больных пищевыми токсикоинфекциями, протекающими на фоне хронического алкоголизма. Материалы. юбилейной Российской научной конференции с международным. участием, посвященной 175-летию со дня рождения С. П. Боткина. Под ред. Б. В. Гайдара. - СПб., 2007, с. 266.
      21. Marzhohova M. Yu. The level of low and medium molecular weight substances as an indicator of endotoxemia in patients with foodborne diseases occurring on a background of chronic alcoholism. Materials of anniversary Russian scientific conference with the international participation, devoted to 175th anniversary of S. P. Botkin. Ed. Gaidar B. V. - St. Petersburg, 2007, p. 266.
      22. Оковитый С. В., Суханов Д. С., Заплутанов В. А., Смагина А. Н. Антигипоксанты в современной клинической практике. Клиническая медицина, 2012, № 9, сс. 63-68. Okovity S. V., Sukhanov D. S., Zaplutanov V. A., Smagina A. N. Antihypoxants in modern clinical practice. Clinical medicine, 2012, № 9, pp. 63-68.
      23. Коновалова М. С. Янтарная кислота против воспалений и опухолей. - СПб.: Весь, 2005. - 128 с.
      24. M. S. Konovalova. Succinic acid against inflammations and tumors. - SPb.: Ves`, 2005. - p.128.
      25. Тихонова Е. О., Ляпина Е. П., Шульдяков А. А. Изучение эффективности патогенетической терапии больных острыми кишечными инфекциями с использованием сукцинатсодержащего препарата Реамберина. Экспериментальная и клиническая фармакология, 2013, 76(1), pp. 11-13.
      26. Tikhonova E. O., Lyapina E. P., Shuldyakov A. A. Efficiency of the pathogenetic therapy of patients with acute intestinal infections with the use of succinate-containing drug Reamberin. Experimental and Clinical Pharmacology, 2013, 76 (1), pp. 11-13.
      27. Скоромец А. А., Никитина В. В., Барышев Б. А. Влияние реамберина на сосудисто-тромбоцитарное и плазменно-коагуляционное звенья гемостаза в плазме крови у доноров in vitro. Вестник Санкт-Петербургской медицинской академии им. И. И. Мечникова, 2003, 4, cc. 132-136.
      28. Skoromets A. A., Nikitina V. V., Baryshev B. A. Influence of reamberin on vascular-platelet and plasma coagulation parts of hemostasis in the blood plasma of donors in vitro. Bulletin of the St. Petersburg Medical Academy of I. I. Mechnikov, 2003, 4, pp. 132-136.
      29. Плоскирева А. А., Горелов А. В., Жучкова С. Н., Бондарева А. В. и др. Современные подходы к интенсивной терапии острых кишечных инфекций у детей. Инфекционные болезни, 2012, т. 10, № 1, сс. 50-55.
      30. Ploskireva A. A., Gorelov A. V., Zhuchkova S. N., Bondarev A. V. and others. Current approaches to intensive therapy of acute intestinal infections in children. Infectious Diseases, 2012, vol.10, № 1, pp. 50-55.

    Full text is published :
    REAMBERIN IN THE COMPLEX THERAPY OF ACUTE INTESTINAL INFECTIONS. Experimental and Clinical Gastroenterology Journal. 2017;138(02):77-85
    Read & Download full text